Polarized Aerobic Training and Vascular Adaptations in Apparently Healthy Individuals

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-50
SponsorUniversity of Ljubljana

About this trial

This randomized controlled trial will investigate the effects of a 6-week polarized aerobic training intervention on vascular and cardiorespiratory function in apparently healthy sedentary adults aged 30-50 years. Polarized training is characterized by a high proportion of low-intensity aerobic exercise combined with a smaller volume of high-intensity interval exercise, potentially providing complementary haemodynamic and physiological stimuli that support vascular adaptations and cardiovascular health. Although polarized training has been extensively studied in athletic populations, its effects on vascular function in sedentary adults remain insufficiently understood.

Thirty participants will be randomly assigned in a 1:1 ratio to either a supervised polarized aerobic training group or a non-exercising control group. The intervention will consist of a 6-week supervised cycle ergometer training program performed three times per week and prescribed according to individual ventilatory thresholds obtained during cardiopulmonary exercise testing. Training sessions will combine low-to-moderate-intensity continuous exercise and high-intensity interval exercise. Participants allocated to the control group will maintain their habitual sedentary lifestyle throughout the study period.

The primary outcome will be endothelial function assessed by brachial artery flow-mediated dilation. Secondary outcomes will include arterial stiffness assessed by pulse wave velocity, central haemodynamics, microvascular function, cardiorespiratory fitness, skeletal muscle function, pulmonary function, respiratory muscle strength, and circulating biomarkers related to vascular health. Outcome measures will be assessed at baseline and after completion of the 6-week intervention period. The findings of this study may improve understanding of vascular and systemic adaptations to polarized aerobic training and help inform future exercise-based strategies for cardiovascular risk reduction in apparently healthy sedentary adults.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Men and women aged 30-50 years

Apparently healthy individuals without diagnosed cardiovascular, metabolic, or renal disease

Sedentary lifestyle verified using the Global Physical Activity Questionnaire (GPAQ) and current physical activity classification criteria

Ambulatory blood pressure values within the normotensive range (<140 mmHg systolic and <90 mmHg diastolic)

Disqualifiers

Ambulatory blood pressure values ≥140 mmHg systolic and/or ≥90 mmHg diastolic

Moderate or high physical activity level according to the Global Physical Activity Questionnaire (GPAQ)

Diagnosed chronic cardiovascular, metabolic, renal, respiratory, or other systemic disease

Use of prescribed medication influencing cardiovascular or metabolic function

Trial design

Design model

Parallel

Treatments tested in this trial

  • Polarized Aerobic Training

    Behavioral

    Participants will undergo a 6-week supervised polarized aerobic training programme performed three times weekly on a cycle ergometer. The intervention will combine low-to-moderate-intensity continuous training and high-intensity interval training prescribed according to individual ventilatory thresholds determined during cardiopulmonary exercise testing. The weekly structure will include two high-intensity interval sessions and one continuous aerobic training session, thereby creating a polarized intensity distribution characterized by a predominance of low-intensity exercise and limited exposure to the moderate-intensity domain. Exercise intensity will be individualized using heart rate and power output targets, and all sessions will be supervised by trained personnel.

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: Polarized Aerobic TrainingExperimental treatment 1 intervention
Group B: Non-Exercising ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Brachial artery flow-mediated dilation (FMD)

Endothelial function will be assessed using brachial artery flow-mediated dilation (FMD) measured by high-resolution ultrasound following a standardized ischemia-reperfusion protocol. FMD will be expressed as the relative (%) increase in brachial artery diameter following cuff release compared with baseline diameter.

Time frame
Baseline and post-intervention (week 6; at least 72 hours after the final exercise session)
2

Flow-mediated slowing (FMS)

Flow-mediated slowing (FMS, %) will be assessed using pulse wave velocity deceleration after occlusion of the brachial artery with an oscillometric device (Vicorder, Skidmore Medical, United Kingdom).

Time frame
Baseline and post-intervention (week 6; at least 72 hours after the final exercise session)
3

Carotid-femoral pulse wave velocity

Carotid-femoral pulse wave velocity will be assessed using an oscillometric device (Vicorder, Skidmore Medical, United Kingdom) and reported in m/s.

Time frame
Baseline and post-intervention (week 6; at least 72 hours after the final exercise session)
4

Brachial-radial pulse wave velocity

Brachial-radial pulse wave velocity will be assessed using an oscillometric device (Vicorder, Skidmore Medical, United Kingdom) and reported in m/s

Time frame
Baseline and post-intervention (week 6; at least 72 hours after the final exercise session)

Secondary outcomes

1

Aortic pulse pressure (AOPP)

Aortic pulse pressure will be assessed using oscillometric pulse wave analysis (Vicorder, software version 4; Skidmore Medical, United Kingdom) and reported in mmHg.

Time frame
Baseline and post-intervention (week 6; at least 72 hours after the final exercise session)
2

Augmentation index

Augmentation index will be assessed using oscillometric pulse wave analysis (Vicorder, software version 4; Skidmore Medical, United Kingdom) and reported as a percentage.

Time frame
Baseline and post-intervention (week 6; at least 72 hours after the final exercise session)
3

Muscle tissue reoxygenation slope (microvascular reactivity)

Muscle tissue reoxygenation following reactive hyperaemia will be assessed using near-infrared spectroscopy during a vascular occlusion-reperfusion protocol. A continuous-wave NIRS system (PortaMon; Artinis Medical Systems, The Netherlands) will be used to record tissue saturation index continuously during baseline, arterial occlusion, and reperfusion. Microvascular reactivity will be quantified as the reoxygenation slope, calculated from the increase in tissue saturation index immediately after cuff release, and reported as percentage points per second (%/s).

Time frame
Baseline and post-intervention (week 6; at least 72 hours after the final exercise session)
4

Skeletal muscle stiffness

Skeletal muscle stiffness (N/m) will be assessed non-invasively using a handheld myotonometer (MyotonPRO; Myoton AS, Estonia). Measurements will be performed with participants in a relaxed, standardised position to assess passive mechanical properties of the quadriceps femoris muscles.

Time frame
Baseline and post-intervention (week 6; at least 72 hours after the final exercise session)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.